Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2508 | NasoVAX Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants. Blood tests will be done to check how much HFB30132A is in the bloodstream and how long the body takes to eliminate it. Participation may include up to ten visits to the study center.
Description: Number of participants experiencing TEAEs
Measure: Number of participants with treatment emergent serious adverse events (TESAEs) Time: From Day 1 to up to Day 30 of the last enrolled subjectDescription: Safety and tolerability will be evaluated in terms of number of participants with TEAEs of special interest (hypersensitivity / anaphylactic reaction / local tolerability)
Measure: Number of participants with treatment emergent adverse events (TEAE) of special interest Time: From Day 1 to up to Day 30 of the last enrolled subjectDescription: Safety and tolerability will be evaluated in terms of number of participants with TEAE
Measure: Number of participants with treatment-emergent adverse events (TEAE) Time: From Day 1 to up to Day 30 of the last enrolled subjectDescription: Safety and tolerability will be evaluated in terms of number of participants with TEAEs
Measure: Number of participants with treatment-emergent adverse events (TEAEs) Time: From Day 1 to up to last follow-up day (Day 270)Description: Safety and tolerability will be evaluated in terms of number of participants with TESAEs
Measure: Number of participants with treatment-emergent serious adverse events (TESAEs) Time: From Day 1 to up to last follow-up day (Day 270)Description: Presence or absence of antibodies against HFB30132A over time
Measure: HFB30132A Anti-drug antibodies Time: From Day 1 to up to last follow-up day (Day 270)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports